Fig. 5: KP minor metabolites. | Translational Psychiatry

Fig. 5: KP minor metabolites.

From: Impact of IDO activation and alterations in the kynurenine pathway on hyperserotonemia, NAD+ production, and AhR activation in autism spectrum disorder

Fig. 5

Plasma levels of xanthurenic acid (XA, A), its sulphoconjugate XA-SO4 (B), and the sum of XA and XA-SO4 (C) in controls (n = 106) and individuals with ASD (n = 90). D Relationship between XA-SO4 and platelet PST-M activity in controls (green) and individuals with ASD (magenta). E Platelet PST-M activity in individuals with ASD with KYN/TRP ≤ 5% (n = 33) and > 5% (n = 57). F Plasma levels of cinnabarinic acid (CA) in controls (n = 106) and individuals with ASD (n = 90). G Plasma levels of STC2 in controls (n = 106) and individuals with ASD (n = 90). H Relationship between plasma CA and STC2 in controls (n = 104) and individuals with ASD (n = 90). I IL22 plasma levels in controls (n = 16) and individuals with ASD (n = 38). J IL22 plasma levels in individuals with ASD and KYN/TRP ≤ 5% (n = 13) or >5% (n = 25). K relationship between CA and IL22 in controls (n = 16), individual with ASD and KYN/TRP ≤ 5% (n = 13), and individuals with ASD and KYN/TRP > 5% (n = 25). Intergroup comparisons were performed using the sum-rank Wilcoxon test. Correlations were calculated using Spearman’s correlation coefficient (ρ).

Back to article page